Announcement under Regulation 30 (LODR)-Updates
Dear Sirs, We enclose a communication pertaining to USFDA approval. This is for your information and records.09-02-2018
09-02-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Stock Holding Pvt Ltd06-02-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Consumer Pvt Ltd06-02-2018
Updates
Dear Sirs, We have noted from the SEBI website that by Adjudication Order dated January 31, 2018, a penalty of Rs. 10 Lac has been imposed on each of Jubilant Life Sciences Limited, Jubilant Stock Holding Private Limited, Mr. Shyam Sunder Bhartia and Mr. Hari Shanker Bhartia. We have not yet received the order and we will evaluate the option of filing an appeal against the said order once we have had the opportunity to review it.01-02-2018
Clarification sought from Jubilant Life Sciences Ltd
The Exchange has sought clarification from Jubilant Life Sciences Ltd with respect to news article appearing on The Economic Times - February 1, 2018 titled "SEBI Fines Jubliant Life, Senior Officials".The reply is awaited.01-02-2018
Bhartia brothers wealthier by Rs 60 bn as stocks rally on improved profits
Jubilant Life Sciences, the bigger of the two businesses, posted its best quarterly profit of Rs 2.13 billion in the December quarter, up 78 per cent year-on-year01-02-2018
Updates
Dear Sirs, We enclose a communication pertaining to USFDA approval. This is for your information and records.30-01-2018
Updates
Sub: Intimation pursuant to Regulation 57(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Payment of Interest on Non-Convertible Debentures Dear Sirs, This is to certify that the Company has duly made the payment of half yearly interest on Non- Convertible Debentures issued on private placement basis on the due date as per details attached. This is for your information and records.29-01-2018
BUY/SELL/HOLD ideas from D-Street experts
Jubilant Life Sciences is a 'Buy' call with a target price of Rs 1,020 and a stop loss of Rs 910.29-01-2018
Q3 performance: Multiple growth triggers for Jubilant Life Sciences
Further gains for stock will depend on listing of subsidiary, debt reduction27-01-2018